Switching from Mounjaro back after side effects: what the data says

What did @katriceblessladymobley actually say?

Honestly, not much verbally. The transcript is song lyrics, not medical commentary. The real content here lives in the caption, where she shares that she hit her goal weight of 165 lbs, has now dropped to 150 lbs, is experiencing side effects from her current GLP-1 medication, and is working with her endocrinologist to switch back to Mounjaro (tirzepatide). She also notes her blood sugar remains "normal." That's a meaningful clinical update, and it's more responsible than most GLP-1 content on this platform.

The hashtags fill in some context: she's lost over 100 lbs (at least 138 lbs by one tag), she has type 2 diabetes, and she's been on Ozempic (semaglutide) at some point. The caption mentions she's "trying to be in maintenance," which suggests she's grappling with something a lot of long-term GLP-1 users don't talk about: what happens after you reach your goal weight.

Does the science back this up?

The core claim, that GLP-1 side effects are a legitimate reason to switch medications, is well-supported. The literature on GLP-1 tolerability shows significant individual variability in adverse effects, and switching between agents is an established clinical strategy.

Tirzepatide (Mounjaro) and semaglutide (Ozempic) work differently. Tirzepatide is a dual GIP/GLP-1 receptor agonist, while semaglutide acts only on GLP-1 receptors. Frías et al. (2021, New England Journal of Medicine) showed tirzepatide produced greater reductions in HbA1c and body weight than semaglutide in the SURPASS-2 trial. Some patients also report different side effect profiles between the two, though head-to-head tolerability data is limited. The decision to switch is genuinely individualized, and involving an endocrinologist, as she's doing, is exactly the right call. Her note that blood sugars remain normal while off Mounjaro is plausible if she's in maintenance and has lost significant weight, since weight loss itself improves insulin sensitivity independent of medication.

What did they get wrong (or right)?

She got the process right. Telling her endocrinologist about side effects before switching medications is textbook patient behavior, not something you see enough of in GLP-1 content online, which tends to glorify the drugs without acknowledging the gastrointestinal toll they take on a significant portion of users.

What's missing is nuance about maintenance dosing. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed that people who stopped tirzepatide after reaching their goal weight regained two-thirds of their lost weight within a year. She's already below her goal weight at 150 lbs, which could indicate she's lost more than intended, possibly from switching medications or reduced appetite without active dosing. That's not a red flag by itself, but it's worth flagging that "maintenance" on GLP-1s is still an evolving clinical concept. There's no approved protocol for stepping down doses to maintain rather than continue losing weight, and that gap deserves more honest conversation.

She also doesn't overclaim. She's not selling anything, not recommending doses, not calling tirzepatide a cure. That puts her ahead of most GLP-1 influencers by a wide margin.

What should you actually know?

Side effects are one of the most underdiscussed parts of long-term GLP-1 use. Nausea, vomiting, and gastroparesis-like symptoms affect a meaningful portion of users. Davies et al. (2021, Lancet Diabetes and Endocrinology) noted that GI adverse events led to discontinuation in a notable percentage of trial participants across multiple GLP-1 agents. The rates differ somewhat between drugs, which is part of why switching between semaglutide and tirzepatide is a legitimate clinical option.

For people with type 2 diabetes, the calculus is more complex than it is for people using GLP-1s purely for weight loss. Blood sugar management is a primary outcome, and if her A1c is genuinely stable without medication, that's a meaningful data point her endocrinologist needs. But stable blood sugar in the short term doesn't mean the underlying insulin resistance has resolved permanently, particularly if weight is regained.

Maintenance after major weight loss on a GLP-1 is one of the most understudied areas in this entire drug class. Patients and clinicians are figuring it out in real time. Her experience is more common than the clinical literature currently reflects.

Bottom line

This video is mostly a personal health update from someone managing type 2 diabetes responsibly, not a medical claim that needs aggressive fact-checking. She's working with her doctor, reporting side effects through the right channels, and not overstating what the drugs do. The underlying science on switching GLP-1s and on what happens to blood sugar during weight maintenance both support the general picture she's describing. The main gap is that long-term maintenance on these drugs is still an open clinical question, and her experience of being below her goal weight is worth watching carefully.